rhabdomyosarcoma |
Disease ID | 178 |
---|---|
Disease | rhabdomyosarcoma |
Manually Symptom | UMLS | Name(Total Manually Symptoms:20) C2681938 | beckwith-wiedemann syndrome C2364133 | infection C1963274 | vasculitis C1264606 | persistent infection C1261473 | soft tissue sarcomas C0581384 | chronic anemia C0334517 | spermatocytic seminoma C0279665 | ovarian mucinous cystadenocarcinoma C0220650 | brain metastasis C0220650 | brain metastases C0153690 | bone metastasis C0153690 | bone metastases C0153676 | pulmonary metastasis C0029089 | ophthalmoplegia C0023903 | hepatoma C0020437 | hypercalcemia C0018133 | graft-versus-host disease C0013533 | echovirus infection C0012739 | disseminated intravascular coagulation C0008626 | chromosomal abnormality |
Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:3) |
Manually Genotype(Total Text Mining Genotypes:0) |
---|
(Waiting for update.) |
All Snps(Total Genotypes:4) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
rs121913529 | 23821038 | 3845 | KRAS | umls:C0035412 | BeFree | By contrast, mylz2:KRAS(G12D) tumors more closely resembled mature skeletal muscle and were most similar to well-differentiated human rhabdomyosarcoma in terms of gene expression. | 0.000814326 | 2013 | KRAS | 12 | 25245350 | C | T,G,A |
rs121913529 | 23705022 | 3845 | KRAS | umls:C0035412 | BeFree | We performed an overexpression screen of chromatin-modifying factors in a KRAS(G12D)-driven zebrafish model for RMS. | 0.000814326 | 2013 | KRAS | 12 | 25245350 | C | T,G,A |
rs121913529 | 20805368 | 3845 | KRAS | umls:C0035412 | BeFree | Mosaicism for oncogenic G12D KRAS mutation associated with epidermal nevus, polycystic kidneys and rhabdomyosarcoma. | 0.000814326 | 2010 | KRAS | 12 | 25245350 | C | T,G,A |
rs28934576 | 21484931 | 7157 | TP53 | umls:C0035412 | BeFree | Patient 1 with LFS and TP53(R273H) developed a rhabdomyosarcoma twice at the ages of 18 months and 21 years. | 0.011867498 | 2011 | TP53 | 17 | 7673802 | C | T,A |
GWASdb Annotation(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
GWASdb Snp Trait(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
Mapped by lexical matching(Total Items:0) |
---|
(Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
---|
(Waiting for update.) |
Chemical(Total Drugs:13) | |||||||||
---|---|---|---|---|---|---|---|---|---|
CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
C0035412 | bortezomib | D000069286 | - | rhabdomyosarcoma | MESH:D012208 | therapeutic | 18342500 | ||
C0035412 | cyclophosphamide | D003520 | 50-18-0 | rhabdomyosarcoma | MESH:D012208 | therapeutic | 18989167 | ||
C0035412 | decitabine | C014347 | 2353-33-5 | rhabdomyosarcoma | MESH:D012208 | therapeutic | 19155313 | ||
C0035412 | cisplatin | D002945 | 15663-27-1 | rhabdomyosarcoma | MESH:D012208 | therapeutic | 15354722 | ||
C0035412 | ifosfamide | D007069 | 3778-73-2 | rhabdomyosarcoma | MESH:D012208 | therapeutic | 11846301 | ||
C0035412 | melphalan | D008558 | 148-82-3 | rhabdomyosarcoma | MESH:D012208 | therapeutic | 11846301 | ||
C0035412 | mesna | D015080 | 19767-45-4 | rhabdomyosarcoma | MESH:D012208 | therapeutic | 3114437 | ||
C0035412 | methotrexate | D008727 | 1959/5/2 | rhabdomyosarcoma | MESH:D012208 | therapeutic | 19821538 | ||
C0035412 | mitoxantrone | D008942 | 65271-80-9 | rhabdomyosarcoma | MESH:D012208 | therapeutic | 6684503 | ||
C0035412 | tretinoin | D014212 | 302-79-4 | rhabdomyosarcoma | MESH:D012208 | therapeutic | 15982179 | ||
C0035412 | valproic acid | D014635 | 99-66-1 | rhabdomyosarcoma | MESH:D012208 | therapeutic | 19155313 | ||
C0035412 | vinblastine | D014747 | 865-21-4 | rhabdomyosarcoma | MESH:D012208 | therapeutic | 15591910 | ||
C0035412 | vincristine | D014750 | - | rhabdomyosarcoma | MESH:D012208 | therapeutic | 11846301 |
FDA approved drug and dosage information(Total Drugs:1) | ||||||||
---|---|---|---|---|---|---|---|---|
DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
MESH:D012208 | velcade | bortezomib | 3.5MG/VIAL | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | Prescription | None | Yes | Yes |
FDA labeling changes(Total Drugs:1) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
MESH:D012208 | 09/14/2015 | velcade | bortezomib | Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) | Effectiveness in pediatric patients with relapsed pre-B ALL has not been established. The activity and safety of Velcade in combination with intensive reinduction chemotherapy was evaluated in pediatric and young adult patients with lymphoid malignancies. There were 140 patients with ALL or LL enrolled and evaluated for safety. No new safety concerns were observed | Labeling | B | - | - | - | Millennium Pharmaceuticals, Inc. | - | FALSE |